Sight Sciences CFO Alison Bauerlein sells shares worth $44,787

Published 04/04/2025, 02:58
Sight Sciences CFO Alison Bauerlein sells shares worth $44,787

Alison Bauerlein, Chief Financial Officer of Sight Sciences , Inc. (NASDAQ:SGHT), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Bauerlein offloaded 19,397 shares of common stock on April 2, 2025, at a price of $2.309 per share. The sale amounted to a total value of $44,787. The transaction occurs as the stock trades near its 52-week low of $2.04, having declined over 60% in the past six months. InvestingPro analysis indicates the stock is currently undervalued, with analysts setting price targets between $2.50 and $5.00.

This transaction was conducted to cover the tax liability associated with the vesting of restricted stock units. Following the sale, Bauerlein retains ownership of 649,794 shares in Sight Sciences. While the company maintains strong liquidity with a current ratio of 9.04, InvestingPro data reveals the company is quickly burning through cash, with analysts not expecting profitability this year. Get access to 10+ additional exclusive ProTips and comprehensive analysis through the Pro Research Report, available with an InvestingPro subscription.

In other recent news, Sight Sciences Inc. reported its fourth-quarter 2024 earnings, revealing a slight miss on both earnings per share and revenue forecasts. The company recorded an EPS of -$0.23, slightly below the forecasted -$0.22, and revenue of $19.1 million, under the expected $20.26 million. Despite a 2% year-over-year increase in total revenue, the company faced challenges in its dry eye segment, with revenue dropping significantly from $1.6 million to $300,000. Meanwhile, surgical glaucoma revenue grew by 9% year-over-year, contributing positively to the overall performance.

Stifel analysts adjusted their price target for Sight Sciences to $4.00 from $5.00, maintaining a Buy rating. This revision followed the company’s revenue miss and challenges in its Surgical Glaucoma segment, attributed to changes in Medicare Local Coverage Determinations. The analysts noted optimism for potential reimbursement for the TearCare product, which could provide future revenue opportunities. Sight Sciences provided revenue guidance for 2025 in the range of $70 million to $75 million, with expectations for initial reimbursement decisions for TearCare in 2025. The company remains focused on achieving cash flow breakeven without additional equity capital, emphasizing strategic growth in its glaucoma and dry eye markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.